Free Trial

NanoVibronix Q2 2023 Earnings Report

NanoVibronix logo
$3.59 -0.18 (-4.77%)
As of 11:49 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NanoVibronix EPS Results

Actual EPS
-$7.15
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NanoVibronix Revenue Results

Actual Revenue
$0.29 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NanoVibronix Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Remove Ads

NanoVibronix Earnings Headlines

[OPEN NOW] New rules to trade options with.
Here’s an update that could make your entire year. But first, a question. Could you get better wins if you applied a new set of rules to your trade? For example, when you meet your criteria to take a trade, could you improve your results by taking the same trade differently? From the audit I just did, it turns out the answer is a resounding YES! I applied a new set of rules to 100 live published trades from 2024. These 100 trades already got a whopping 69% win rate – taking a $10k model account risking 10% per trade to $63,304. But what happened when we applied these new rules? We got an 85.1% win rate and sent the same $10k account risking 10% per trade to over $200k!
NanoVibronix announces UroShield health service study data published
See More NanoVibronix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NanoVibronix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NanoVibronix and other key companies, straight to your email.

About NanoVibronix

NanoVibronix (NASDAQ:NAOV), through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

View NanoVibronix Profile

More Earnings Resources from MarketBeat